ClearPoint Neuro (CLPT) CEO’s trust sells 2,943 shares in 10b5-1 plan

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. insider activity: a trust associated with CEO and President Joseph Burnett sold 2,943 shares of ClearPoint Neuro common stock on 01/26/2026 at a weighted average price of $15.57 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.

After this sale, the Joseph M. Burnett Trust held 214,116 shares indirectly for Mr. Burnett, and he also held 11,565 shares directly. The sale price range was from $15.23 to $15.65 per share, and detailed trade breakdowns are available from the company or the SEC staff upon request.

Insider Trade Summary

Net Seller: 2,943 shares ($45,823)

Net Sell 2 txns

Insider BURNETT JOSEPH

Role CEO and President

Sold 2,943 shs ($46K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,943	$15.57	$46K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 214,116 shares (Indirect, See Footnote); Common Stock — 11,565 shares (Direct)

Footnotes (1)

1. The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. Represents a weighted average sales price per share. The shares were sold at prices ranging from $15.23 to $15.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURNETT JOSEPH

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		S(1)		2,943	D	$15.57(2)	214,116	I	See Footnote(3)
Common Stock								11,565	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $15.23 to $15.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

	/s/ Danilo D'Alessandro, by Power of Attorney for Joseph M. Burnett	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report on January 26, 2026?

A trust associated with ClearPoint Neuro’s CEO sold 2,943 shares. The Joseph M. Burnett Trust executed the sale of common stock at a weighted average price of $15.57 per share on 01/26/2026 under a Rule 10b5-1 trading plan.

Who executed the recent ClearPoint Neuro (CLPT) share sale reported on Form 4?

The Joseph M. Burnett Trust executed the share sale. The trust, for which CEO and President Joseph Burnett serves as trustee, sold 2,943 shares of ClearPoint Neuro common stock, with Mr. Burnett reported as the indirect beneficial owner.

At what prices were the ClearPoint Neuro (CLPT) shares sold in the latest insider trade?

The shares were sold at prices between $15.23 and $15.65 per share. The reported weighted average sales price was $15.57 per share, and detailed trade-by-trade pricing is available from the issuer or SEC staff upon request.

How many ClearPoint Neuro (CLPT) shares does Joseph Burnett own after the reported transaction?

Joseph Burnett indirectly holds 214,116 shares and directly holds 11,565 shares. The 214,116 shares are held by the Joseph M. Burnett Trust, where he is trustee, while 11,565 shares are reported as directly owned following the January 26, 2026 sale.

Was the ClearPoint Neuro (CLPT) insider sale made under a Rule 10b5-1 plan?

Yes, the sale was made under a Rule 10b5-1 trading plan. The written plan was adopted by the reporting person on June 11, 2025, allowing pre-arranged sales of ClearPoint Neuro shares according to predetermined instructions.

What role does Joseph Burnett hold at ClearPoint Neuro (CLPT) in this Form 4 filing?

Joseph Burnett is ClearPoint Neuro’s CEO, President, and a director. The Form 4 identifies him as both an officer (CEO and President) and a director, with reported indirect ownership through a trust and direct ownership of additional shares.